Skip to main content

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.

Publication ,  Journal Article
Ogino, S; Meyerhardt, JA; Irahara, N; Niedzwiecki, D; Hollis, D; Saltz, LB; Mayer, RJ; Schaefer, P; Whittom, R; Hantel, A; Benson, AB ...
Published in: Clin Cancer Res
December 1, 2009

PURPOSE: Alterations in the RAS and RAF pathway relate to epigenetic and epigenomic aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal cancer predicts resistance to anti-epidermal growth factor receptor (EGFR)-targeted therapy (cetuximab or panitumumab). It remains uncertain, however, whether KRAS mutation predicts prognosis or clinical outcome of colon cancer patients independent of anti-EGFR therapy. METHODS: We conducted a study of 508 cases identified among 1,264 patients with stage III colon cancer who enrolled in a randomized adjuvant chemotherapy trial (5-fluorouracil, leucovorin with or without irinotecan) in 1999-2001 (CALGB 89803). KRAS mutations were detected in 178 tumors (35%) by pyrosequencing. Kaplan-Meier and Cox proportional hazard models assessed the prognostic significance of KRAS mutation and adjusted for potential confounders including age, sex, tumor location, tumor/node stage, performance status, adjuvant chemotherapy arm, and microsatellite instability status. RESULTS: Compared with patients with KRAS-wild-type tumors, patients with KRAS-mutated tumors did not experience any difference in disease-free, recurrence-free, or overall survival. The 5-year disease-free, recurrence-free, and overall survival rates (KRAS-mutated versus KRAS-wild-type patients) were 62% versus 63% (log-rank P = 0.89), 64% versus 66% (P = 0.84), and 75% versus 73% (P = 0.56), respectively. The effect of KRAS mutation on patient survival did not significantly differ according to clinical features, chemotherapy arm, or microsatellite instability status, and the effect of adjuvant chemotherapy assignment on outcome did not differ according to KRAS status. CONCLUSIONS: In this large trial of chemotherapy in stage III colon cancer patients, KRAS mutational status was not associated with any significant influence on disease-free or overall survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

December 1, 2009

Volume

15

Issue

23

Start / End Page

7322 / 7329

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • Oncogene Protein p21(ras)
  • Mutation
  • Middle Aged
  • Microsatellite Repeats
  • Male
  • Irinotecan
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ogino, S., Meyerhardt, J. A., Irahara, N., Niedzwiecki, D., Hollis, D., Saltz, L. B., … Southwest Oncology Group, . (2009). KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res, 15(23), 7322–7329. https://doi.org/10.1158/1078-0432.CCR-09-1570
Ogino, Shuji, Jeffrey A. Meyerhardt, Natsumi Irahara, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, et al. “KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Clin Cancer Res 15, no. 23 (December 1, 2009): 7322–29. https://doi.org/10.1158/1078-0432.CCR-09-1570.
Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 1;15(23):7322–9.
Ogino, Shuji, et al. “KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Clin Cancer Res, vol. 15, no. 23, Dec. 2009, pp. 7322–29. Pubmed, doi:10.1158/1078-0432.CCR-09-1570.
Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS, Cancer and Leukemia Group B, North Central Cancer Treatment Group, Canadian Cancer Society Research Institute, Southwest Oncology Group. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 1;15(23):7322–7329.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

December 1, 2009

Volume

15

Issue

23

Start / End Page

7322 / 7329

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • Oncogene Protein p21(ras)
  • Mutation
  • Middle Aged
  • Microsatellite Repeats
  • Male
  • Irinotecan
  • Humans